About Ovagen
Ovagen is a company based in Ireland founded in 2000 by Leonard Moran. Ovagen has raised $25.21 million across 8 funding rounds from investors including European Investment Bank, Enterprise Ireland and European Union. Ovagen operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and IDT Biologika, among others.
- Headquarter Mayo, Ireland
- Founders Leonard Moran
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25.21 M (USD)
in 8 rounds
-
Latest Funding Round
$2.16 M (USD), Unspecified
Oct 29, 2024
-
Investors
European Investment Bank
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ovagen
Ovagen has successfully raised a total of $25.21M across 8 strategic funding rounds. The most recent funding activity was a Unspecified round of $2.16 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ovagen
Ovagen has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Enterprise Ireland and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity & debt fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
A platform connecting angel investors to startups in Ireland.
|
Locked | Locked | Locked |
Investor details for Ovagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ovagen
Investment portfolio details for Ovagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ovagen
Detailed financials for Ovagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ovagen Comparisons
Peer comparison for Ovagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ovagen
Ovagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and IDT Biologika, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
|
| Locked | Locked | Locked |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Detailed competitors of Ovagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ovagen
Complete news archive for Ovagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ovagen
Ovagen was founded in 2000 and raised its 1st funding round 8 years after it was founded.
Ovagen is headquartered in Ireland. It is registered at Mayo, Ireland.
Leonard Moran is the current CEO of Ovagen. They have also founded this company.
Ovagen is a funded company, having raised a total of $25.21M across 8 funding rounds to date.
Ovagen was founded in 2000 and is based in Mayo, Ireland. Operations focus on the biotechnology sector, where germ-free and specific pathogen-free eggs are produced for use in vaccine development and antibody manufacturing. Services include specialized egg production tailored to pharmaceutical needs, ensuring controlled environments free from contaminants. The company supports research and production activities in the immunology and biopharma industries across Europe.
Ovagen's top competitors include KBI Biopharma, Aldevron and Laurus Bio.
Ovagen has 10 investors. Key investors include European Investment Bank, Enterprise Ireland, European Union, Western Development Commission, and Irrus Investments.